EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT01401530
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT01398410
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 472
- Registration Number
- NCT01397448
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01390714
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 2157
- Registration Number
- NCT01321567
A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01306318
- Locations
- 🇮🇳
Manipal AcuNova KH Clinical Research Center, Manipal, Karnataka, India
A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 239
- Registration Number
- NCT01300312
- Locations
- 🇮🇳
Deore Hospital, Aurangabad, Maharashtra, India
🇮🇳Department of Orthopedics, Government Medical College, Aurangabad, Maharashtra, India
🇮🇳Department of Orthopedics, Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, Maharashtra, India
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT01278407
A Study of E7080 in Subjects With Solid Tumor
- First Posted Date
- 2010-12-30
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT01268293
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT01264822
© Copyright 2024. All Rights Reserved by MedPath